Activity Provided By:

Relias LLC

FcRn and Myasthenia Gravis

Overview / Abstract:	Target Audience This activity has been designed to meet the educational needs of physicians specializing in neurology and ophthalmology who may be involved in the diagnosis and care of individuals with MG. Other healthcare providers, including neurology NPs and PAs, may also participate. Program Overview This 30-minute CME program discusses how the FcRn system can impact myasthenia gravis and how FcRn antagonists can be used to treat this rare condition. Learning Objectives After participating in the activity, learners should be better able to: Describe the role of FcRn in MG. Describe the efficacy of the treatment options for MG that target FcRn. Compare the safety of the treatment options for MG that target FcRn.
Expiration	Nov 26, 2025
Discipline(s)	Physician CME
Format	Online
Credits / Hours	0.5 AMA PRA Category 1 Credit(s)™
Accreditation	ACCME
Presenters / Authors / Faculty	Faculty Richard J. Nowak, MD, MS Richard J. Nowak, MD, MS Director, Program in Clinical & Translational Neuromuscular Research (CTNR) Director, Yale Myasthenia Gravis Clinic Associate Professor of Neurology Division of Neuromuscular Medicine Department of Neurology Yale School of Medicine New Haven, CT
Sponsors / Supporters / Grant Providers	Argenx
Keywords / Search Terms	Relias LLC Relias LLC., FreeCME., Myasthenia Gravis Free CE CME

Access Activity

CORE Higher Education Group, CESearchEngine.com, and our advertising partners do not endorse and do not verify the accuracy of the content in the activities presented on the CESearchEngine.com website or within our mobile apps.CORE Higher Education Group, CESearchEngine.com, and our advertising partners are not responsible for errors, omissions, or misrepresentations contained within activities presented on the CESearchEngine website or within our mobile apps. For complete details, please read the CESearchEngine.com Terms of Service. Site Map